Cart
sales@molnova.com
Officinalisinin I
CAS No. 57944-18-0
Officinalisinin I ( —— )
Catalog No. M18844 CAS No. 57944-18-0
Officinalisinin I can effectively reduce the blood glucose and protect nerve injuryin diabetic mice.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 81 | In Stock |
|
| 10MG | 115 | In Stock |
|
| 25MG | 194 | In Stock |
|
| 50MG | 286 | In Stock |
|
| 100MG | 422 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOfficinalisinin I
-
NoteResearch use only, not for human use.
-
Brief DescriptionOfficinalisinin I can effectively reduce the blood glucose and protect nerve injuryin diabetic mice.
-
DescriptionOfficinalisinin I can effectively reduce the blood glucose and protect nerve injuryin diabetic mice.
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number57944-18-0
-
Formula Weight921.07
-
Molecular FormulaC45H76O19
-
Purity98%
-
Solubility——
-
SMILESC[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@H]5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C)OC1(CC[C@H](C)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liu J, et al. Study on hypoglycemic mechanism and central nerve protection of Officinalisinin I in Rhizoma Anemarrhenae[J]. China Journal of Traditional Chinese Medicine & Pharmacy, 2017.
molnova catalog
related products
-
Asperulosidic acid
Asperulosidic acid has anti-tumor, anti-oxidant, and anti-inflammatory activities.ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways.
-
VX-11e
A potent, selective, and orally bioavailable inhibitor of ERK2 with Ki of <2 nM.
-
XMD17-109
XMD17-109 is a novel, specific ERK-5 inhibitor with an EC50 4.2 uM in HEK293 cells.
